{"id":"W2921940659","doi":"10.1200/jco.2019.37.7_suppl.144","title":"Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Adverse effect; Abiraterone acetate; Internal medicine; Placebo; Enzalutamide; Randomized controlled trial; Androgen deprivation therapy; Oncology; Cancer; Androgen receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003712247,0.0004991597,0.001003847,0.0003608108,0.0001459014,0.0007168159,0.0006794614,0.0004101463,0.001451726],"category_scores_gemma":[0.003195175,0.0002608678,0.001716298,0.0006426445,0.0002017809,0.0004752267,0.0003785428,0.001067991,0.0001650536],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005502226,"about_ca_system_score_gemma":0.0007902243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001775593,"about_ca_topic_score_gemma":0.002935249,"domain_scores_codex":[0.9989048,0.0006721513,0.0000634186,0.0001289089,0.0001557886,0.00007490181],"domain_scores_gemma":[0.9972263,0.0008015489,0.001054474,0.0002893417,0.0002338636,0.0003944651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6812172,0.002708156,0.185668,0.001188843,0.01657755,0.0001770458,0.0001943852,0.004466221,0.00791272,0.000276543,0.004540049,0.09507334],"study_design_scores_gemma":[0.1446925,0.07776278,0.7380351,0.00009737733,0.02070797,0.0007971576,0.00007884639,0.007438391,0.003265483,0.0004415858,0.006607635,0.00007505816],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895372,0.003565476,0.0006882256,0.0001567696,0.00003912671,0.0002958698,0.004319432,0.00004973077,0.001348226],"genre_scores_gemma":[0.9939451,0.0005623541,0.0006479209,0.0001343896,0.00005385479,0.0001786495,0.004097543,0.000009529735,0.0003707495],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003712247,"threshold_uncertainty_score":0.01963252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05830491259392324,"score_gpt":0.4217284244402997,"score_spread":0.3634235118463765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}